CClinicalTrials.gg
WithdrawnNCT03282292PRECiSEUpdated Nov 18, 2023

Central Venous Catheter Insertion Site and Colonization in Pediatric Cardiac Surgery

An interventional study of Internal jugular vein CVC insertion in Central Line-associated Bloodstream Infection (CLABSI), Central Venous Catheter Associated Bloodstream Infection and Heart; Surgery, Heart, Functional Disturbance as Result, sponsored by IRCCS Policlinico S. Donato. Withdrawn at 1 site in Italy. Open to participants aged Up to 1 Year. Per ClinicalTrials.gov, last updated 2023-11-18.

Sponsored by IRCCS Policlinico S. Donato · Not applicable, Interventional, and Prevention

Why this study was withdrawn
Co-PI responsible for study procedures moved to another hospital
Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
Up to 1 Year
Sex
All
01

Study summary

Randomized controlled trial comparing femoral vs internal jugular insertion site of central venous catheters (CVC) in newborns and infants undergoing cardiac surgery. The experimental hypothesis is that the jugular insertion site is superior to the femoral in terms of catheter colonization.

Read the detailed description

Background: in adult patients, the femoral site of insertion of CVC is notoriously at higher risk of colonization and central-line associated bloodstream infection (CLABSI) than other sites (jugular or subclavian). In pediatric patients, the femoral site is more commonly used than in adult patients, but there is no sound data on catheter colonization and CLABSI related to the insertion site. The experimental hypothesis of this randomized controlled trial (RCT) is that the jugular insertion site is less likely to induce catheter colonization and CLABSI than the femoral site.

Methods: 160 patients under 1 year and scheduled for cardiac surgery will be included in this RCT; patients will be randomly allocated to the jugular (J Group) or Femoral (F Group). CVC insertion will be performed by one out of three selected expert operators.

The primary endpoint is the catheter colonization based on identification of bacterial grow into the catheter at removal time; CLABSI and CRBSI rate based on the same bacterial identification into the catheter tip and in the blood culture performed in case of signs and symptoms of infection.

Secondary endpoints are mechanical complications defined as arterial puncture immediately identified during procedure, hemothorax and pneumothorax; and procedural difficulty during insertion defined as number of attempts, no guidewire progress, duration of the procedure (time from the completion of the sterile precaution barriers and the catheter fixation.

02

Conditions studied

  • Central Line-associated Bloodstream Infection (CLABSI)
  • Central Venous Catheter Associated Bloodstream Infection
  • Heart; Surgery, Heart, Functional Disturbance as Result
  • Congenital Heart Disease
  • Newborn; Infection
03

Who can participate

Ages eligible
Up to 1 Year
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

Planned cardiac surgery Age \<1 year Eligibility for both insertion sites (jugular and femoral) for CVC Availability of at least one out of the three chosen expert operators

Exclusion criteria

Exclusion Criteria:

Emergency surgery Known vascular anatomic anomalies Previous cardiac surgery in the last 6 months No expert operator availability Intensive Care unit before surgery Central venous catheter inside at the time of randomization

Withdraw criteria (only for the first endpoint):

Impossibility to placement catheter in the selected site.

04

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Jugular

    CVC insertion in the left or right internal jugular vein

    Procedure: Internal jugular vein CVC insertion

  • Active comparator
    Femoral

    CVC insertion in the right or left femoral vein

    Procedure: Internal jugular vein CVC insertion

Interventions

  • ProcedureInternal jugular vein CVC insertion

    Double lumen CVC insertion in the internal jugular vein

05

What researchers measure

Primary outcomes

  1. CVC colonization

    CVC positive culture after removal

    Time frame: 14 days

  2. CRBSI

    Positive CVC culture and blood stream infection for the same organism

    Time frame: 14 days

  3. CLABSI

    A laboratory-confirmed bloodstream infection where central line was in place for more than 48h.

    Time frame: More than 48 hours

Secondary outcomes

  1. Mechanical complications

    Defined as arterial puncture; hemothorax; pneumothorax

    Time frame: 1 day

  2. Procedural difficulty

    Defined by number of attempts; no guidewire progress

    Time frame: 1 hour

06

Study locations

1 site
  • IRCCS Policlinico S.Donato
    San Donato Milanese, Milan 20097, Italy
07

References and documents

Publications

  • Collignon P, Soni N, Pearson I, Sorrell T, Woods P. Sepsis associated with central vein catheters in critically ill patients. Intensive Care Med. 1988;14(3):227-31. doi: 10.1007/BF00717995. PubMed 3379183 ↗
  • Pearson ML. Guideline for prevention of intravascular device-related infections. Part I. Intravascular device-related infections: an overview. The Hospital Infection Control Practices Advisory Committee. Am J Infect Control. 1996 Aug;24(4):262-77. doi: 10.1016/s0196-6553(96)90058-9. No abstract available. PubMed 8870910 ↗
  • de Jonge RC, Polderman KH, Gemke RJ. Central venous catheter use in the pediatric patient: mechanical and infectious complications. Pediatr Crit Care Med. 2005 May;6(3):329-39. doi: 10.1097/01.PCC.0000161074.94315.0A. PubMed 15857534 ↗
  • Karapinar B, Cura A. Complications of central venous catheterization in critically ill children. Pediatr Int. 2007 Oct;49(5):593-9. doi: 10.1111/j.1442-200X.2007.02407.x. PubMed 17875082 ↗
  • Casado-Flores J, Barja J, Martino R, Serrano A, Valdivielso A. Complications of central venous catheterization in critically ill children. Pediatr Crit Care Med. 2001 Jan;2(1):57-62. doi: 10.1097/00130478-200101000-00012. PubMed 12797890 ↗
  • Richards MJ, Edwards JR, Culver DH, Gaynes RP. Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System. Crit Care Med. 1999 May;27(5):887-92. doi: 10.1097/00003246-199905000-00020. PubMed 10362409 ↗
  • Stenzel JP, Green TP, Fuhrman BP, Carlson PE, Marchessault RP. Percutaneous femoral venous catheterizations: a prospective study of complications. J Pediatr. 1989 Mar;114(3):411-5. doi: 10.1016/s0022-3476(89)80559-1. PubMed 2921683 ↗
  • He C, Vieira R, Marin JR. Utility of Ultrasound Guidance for Central Venous Access in Children. Pediatr Emerg Care. 2017 May;33(5):359-362. doi: 10.1097/PEC.0000000000001124. PubMed 28471906 ↗
  • Sanchez Sanchez A, Giron Vallejo O, Ruiz-Pruneda R, Fernandez Ibieta M, Reyes Rios PY, Villamil V, Martinez-Castano I, Rojas Ticona J, Gimenez Aleixandre MC, Ruiz Jimenez JI. [Use of ultrasound for placement of central venous catheters in pediatrics: results of a national survey]. Cir Pediatr. 2017 Jan 25;30(1):9-16. Spanish. PubMed 28585784 ↗
  • Silvetti S, Aloisio T, Cazzaniga A, Ranucci M. Jugular vs femoral vein for central venous catheterization in pediatric cardiac surgery (PRECiSE): study protocol for a randomized controlled trial. Trials. 2018 Jun 25;19(1):329. doi: 10.1186/s13063-018-2717-1. PubMed 29941012 ↗

Individual participant data

Plan to share: Yes — The dataset will be made available at reasonable request

Supporting information: Study protocol, Sap

08

Registry details

Key details

Study ID
NCT03282292
Lead sponsor
IRCCS Policlinico S. Donato
Responsible party
Marco Ranucci (Director Clinical Research, IRCCS Policlinico S. Donato) — Principal investigator
First posted
Sep 13, 2017
Start date
Sep 12, 2017
Primary completion
Sep 12, 2019
Completion
Oct 12, 2019
Last update
Nov 18, 2023

Study contacts

Marco Ranucci, MD
study director · IRCCS Policlinico S. Donato

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion